Tango Therapeutics TNGX Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's operating lease right-of-use asset amortization?
- Tango Therapeutics (TNGX) reported operating lease right-of-use asset amortization of $972K in Q1 2026.
- How has Tango Therapeutics's operating lease right-of-use asset amortization changed year-over-year?
- Tango Therapeutics's operating lease right-of-use asset amortization decreased by 4.0% year-over-year, from $1.01M to $972K.
- What is the long-term trend for Tango Therapeutics's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Tango Therapeutics's operating lease right-of-use asset amortization has grown at a 38.7% compound annual growth rate (CAGR), from $1.07M to $3.96M.